BIA 10‐2474: Some Lessons are Clear but Important Questions Remain Unanswered-Reference-Cited by-同舟云学术

BIA 10‐2474: Some Lessons are Clear but Important Questions Remain Unanswered

Published:2022-01-10 Issue:2 Volume:111 Page:343-345
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Peck Richard W.¹,Holstein Sarah A.²,Graaf Piet H.³⁴

Affiliation:

1. Pharma Research and Development Roche Innovation Center Basel Basel Switzerland

2. Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska USA

3. Certara Canterbury UK

4. Leiden University Leiden The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2495

Reference10 articles.

1. After the London tragedy, is it still possible to consider Phase I is safe?

2. Safety, tolerability, and pharmacokinetics of FAAH inhibitor BIA 10‐2474: a double‐blind, randomized, placebo‐controlled study in healthy volunteers;Rocha J.F.;Clin. Pharmacol. Ther.,2022

3. De‐risking clinical trials: The BIAL phase I trial in foresight;Cohen A.;Clin. Pharmacol. Ther.,2022

4. Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

5. Report by the Temporary Specialist Scientific Committee (TSSC)."FAAH (Fatty Acid Amide Hydrolase)" on the causes of the accident during a Phase 1 clinical trial in Rennes in January 2016. Accessed November 16 2021.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of the Endocannabinoid System in Metabolic Control Processes and in the Pathogenesis of Metabolic Syndrome: An Update;Biomedicines;2023-01-21

2. How artificial intelligence enables modeling and simulation of biological networks to accelerate drug discovery;Frontiers in Drug Discovery;2022-10-04

3. Probability of Success in Drug Development;Clinical Pharmacology & Therapeutics;2022-04-19